Fuzhou Changfuxing New Drug Development

Fuzhou Changfuxing New Drug Development is a Chinese biotechnology company that serves as the primary innovative drug research and development subsidiary of Fujian Cosunter Pharmaceutical. Established in 2001 and led by Dr. Lin-Hua Zhang, the company specializes in the discovery and clinical advancement of small molecule therapeutics for liver diseases, infectious diseases, and oncology. Its pipeline is anchored by a comprehensive portfolio of Hepatitis B (HBV) candidates aimed at achieving a functional cure, alongside programs for non-alcoholic steatohepatitis (NASH) and c-Met-positive solid tumors. The company achieved a significant milestone with the development of Leritrelvir (GST-HG171), a 3CL protease inhibitor that received emergency use authorization in China for the treatment of COVID-19. Fuzhou Changfuxing operates as a high-tech enterprise, leveraging its expertise in medicinal chemistry and molecular biology to drive its parent company's transition from a generic manufacturer to an innovation-led pharmaceutical leader.